NHS: Drugs
The question
To ask the Secretary of State for Health and Social Care, what progress his Department has made on the review of early access to medicines.
Answered by Dr Zubir Ahmed
The Early Access to Medicines Scheme (EAMS), is an existing pathway across the regulatory and access system designed to support innovative treatments being available to patients who need them earlier in the development cycle, outside of a clinical trial. The Government is collaborating across the regulatory system to continuously review the effectiveness of these pathways.
Pharmaceutical companies may also put in place arrangements to provide early access to medicines outside EAMS. Working with colleagues at NHS England, the Department is continuing to engage with companies and patient groups regarding early access schemes that are enabled by manufacturers providing free of charge medicines, in advance of any recommendation from the National Institute for Health and Care Excellence. We are presently working to get a fuller picture of the costs of, and barriers to, and opportunities for early access schemes being offered by National Health Service trusts.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →